Company Focus
CVS Health
Latest CVS Health News
Pharmaceutical
Following the news that Donald Trump is the winner of the 2024 US Presidential Election, Morningstar Equity analyst Julie Utterback has published a new note about the impact of this on the managed-care industry. 7 November 2024
Related News
Insights
Company Spotlight
A global biotech developing of novel antibody-based drugs with innovative technologies.
Latest News & Features of interest to CVS Health
Biotechnology
A quiet shift with potentially big implications for cancer drug access is underway in the UK. In June, the country’s health technology assessor, NICE, recommended GSK’s Blenrep (belantamab mafodotin) in multiple myeloma. 14 July 2025
Pharmaceutical
Germany’s Bayer has announced that the US Food and Drug Administration (FDA) has approved Kerendia (finerenone) to treat patients with heart failure (HF) with left ventricular ejection fraction (LVEF) ≥40%, following the agency’s Priority Review of its supplemental New Drug Application (sNDA). 14 July 2025
Pharmaceutical
Japan’s largest pharma company Takeda today announced that all primary and secondary endpoints were met in two Phase III randomized, double-blind, placebo-controlled studies of oveporexton (TAK-861). 14 July 2025
Biotechnology
The Amsterdam District Court has delivered a ruling in the lawsuit brought by Farma ter Verantwoording (FtV) — The Pharmaceutical Accountability Foundation— against US drugmaker AbbVie. 14 July 2025
Pharmaceutical
South Korean biotech Illimis Therapeutics has raised 58 billion won ($42 million) in a series B round to advance its GAIA platform into the preclinical stage and expand its drug development programs targeting Alzheimer’s disease and immune disorders. 14 July 2025
Pharmaceutical
UK pharma major AstraZeneca today announced positive high-level results from the baxdrostat BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension. 14 July 2025
Pharmaceutical
China’s vaccine landscape is shifting after local biotech Xiamen Innovax Biotech unveiled the country’s first domestically developed nine-valent HPV vaccine, Cecolin 9, at a price far below that of the incumbent Gardasil 9. The new shot is being offered at around $70 per dose—less than half the typical price of Merck & Co’s (NYSE: MRK) product in the country. 14 July 2025
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorized the use of Bayer's Lynkuet (elinzanetant) for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. 14 July 2025
Pharmaceutical
Japanese drugmaker Eisai today revealed that it has launched its Urece (dotinurad) in China as a treatment for gout. 14 July 2025
Biotechnology
US late-stage oncology-focused Revolution Medicines and Iambic Therapeutics, which is developing novel medicines using its AI-driven discovery and development platform, today announced a technology and research collaboration to pursue novel drug candidates using Iambic’s leading AI models. 13 July 2025
Latest In Brief for CVS Health
Pharmaceutical
Ireland-based biopharma Jazz Pharmaceuticals has been called out for a couple of indiscretions by The Prescription Medicines Code of Practice Authority (PMCPA), which was established by the Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry. 11 July 2025
Latest Relevant Ones To Watch News
US pharma giant Merck & Co today revealed it has made a bid to acquire UK-based lung therapy company Verona Pharma, sending the latter’s shares up 20.4% to $104.61 in pre-market activity. 13 July 2025
30 June 2025
17 June 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze